Obesity, diet, & lifestyle interventions

Browse the latest news, expert commentary, and educational content on obesity and lifestyle interventions.

Highlights

19-10-2021 | Tirzepatide | News

Tirzepatide preferable to glargine when OADs fail in SURPASS-4

Tirzepatide provides better glucose control than insulin glargine in people with type 2 diabetes taking multiple oral antidiabetes medications, report the SURPASS-4 investigators in The Lancet.

13-10-2021 | Hypoglycemia | View from the clinic | Article

Endemic hypoglycemia

In the final article in this series, Sanjay Kalra highlights region-specific causes of hypoglycemia requiring a tailored management approach.

15-07-2021 | Epidemiology | News

Global variation in optimal BMI, age cutoffs for diabetes screening

Researchers find large geographic differences in the influence of BMI and age on the risk for type 2 diabetes in low- and middle-income countries.

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Image Credits

Injection pen in stomach/© Mauricio / stock.adobe.com, Sanjay Kalra, Doctor checking patient's blood glucose/© SDI Productions / Getty Images / iStock, STEP trials/© Rawf8 / stock.adobe.com, DiRECT Teaser image

Medicine Matters Diabetes

Obesity, diet, & lifestyle interventions

Browse the latest news, expert commentary, and educational content on obesity and lifestyle interventions.

Highlights

Tirzepatide preferable to glargine when OADs fail in SURPASS-4

Endemic hypoglycemia

Global variation in optimal BMI, age cutoffs for diabetes screening

Semaglutide for weight loss: The STEP and SELECT trials

More on obesity & lifestyle interventions

Rival gastric surgery approaches have similar effects on liver fat

Promising phase 2 results for long-acting amylin analog cagrilintide

Semaglutide 2.4 mg receives EMA approval for obesity

One in 20 may achieve type 2 diabetes remission in routine care

DiRECT: Type 2 diabetes remission through weight management

Conference report: SAFES summit 2021

Tirzepatide preferable to glargine when OADs fail in SURPASS-4

Announcing an upcoming webinar on heart failure

Endemic hypoglycemia

DiRECT insights highlight ‘ongoing struggle’ of maintaining weight loss

Semaglutide treatment may reduce systemic inflammation

SoliMix trial supports iGlarLixi for type 2 diabetes

Insulin resistance linked to arterial stiffness in type 1 diabetes

Stay informed with Medicine Matters